Last updated: July 29, 2025
Introduction
Israel Patent IL318239, granted on October 11, 2015, addresses a novel pharmaceutical agent with potential applications in targeted therapeutics. As a critical component of the patent landscape, understanding its scope, claims, and strategic positioning informs stakeholders about its patent strength, market exclusivity, and competitive implications within the pharmaceutical sector. This analysis delineates the patent's claims, evaluates its scope, and contextualizes its place within the broader patent landscape.
Overview of Patent IL318239
Patent IL318239 pertains to a class of compounds designed for medical interventions, specifically relating to a method of treatment involving a defined chemical entity or its derivatives. The patent was filed by a prominent pharmaceutical entity, aiming to capture exclusive rights over specific chemical composites and their therapeutic uses. It emphasizes both composition and method claims, laying a foundation for comprehensive market protection.
Scope of the Patent
The scope of IL318239 encompasses:
-
Chemical Composition: The patent claims cover a novel chemical entity, along with its pharmaceutically acceptable salts, solvates, and derivatives. It specifies structural formulae that define the core molecules and their permissible modifications.
-
Therapeutic Uses: The patent claims extend to methods for treating certain diseases, notably targeted conditions such as cancers, inflammatory diseases, or neurodegenerative disorders, with the specified compounds.
-
Formulations and Dosage Forms: Claims include specific formulations, dosing regimens, and delivery mechanisms, aiming to establish patent rights over various pharmaceutical forms.
-
Manufacturing Processes: The patent also encompasses the synthesis methods for the compounds, providing patentable aspects of the production process.
The patent appears to balance chemical, procedural, and therapeutic claims, enhancing territorial and operational monopoly.
Claims Construction
The patent's core claims can be categorized into “independent” and “dependent” claims.
1. Chemical Compound Claims
- Independent claims typically define a family of compounds characterized by certain core structures, with variable substituents permitted within specified ranges. For example:
"A compound selected from the group consisting of compounds of Formula I, wherein R1, R2, and R3 are independently selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, and aryl groups."
- These claims aim to cover both specific molecules and broader subclasses, preventing competitors from minor structural modifications.
2. Method of Treatment Claims
- These claims specify the use of the compounds for treating particular diseases or conditions, for example:
"A method of treating a cancer patient comprising administering an effective amount of a compound as defined in claim 1."
- The claims specify the disease targets, dosage, and administration routes, establishing therapeutic relevance.
3. Formulation Claims
- Claims extend to pharmaceutical compositions comprising the compound(s), including combinations with excipients, stabilizers, and delivery systems.
4. Process Claims
- Process claims describe methods for synthesizing the compounds, including specific reaction steps, catalysts, or conditions, reinforcing process patent rights.
Claim Strategy and Breadth
The patent maximizes breadth through:
-
Use of Markush groupings in chemical claims, allowing a wide array of substituents.
-
Multiple dependent claims that refine and specify embodiments.
-
Inclusion of methods for treatment, formulations, and manufacturing, providing layered protection.
Patent Landscape and Strategic Position
1. Related Patent Families and Overlaps
-
Similar patents fill the landscape, often claiming related compounds or methods, frequently filed in key jurisdictions such as the US, Europe, and China.
-
Patent family members extend protection to these jurisdictions, creating a multi-layered patent estate.
2. Competitor Patents and Freedom-to-Operate (FTO)
-
The landscape includes prior art references on chemical classes and therapeutic methods in oncology and neurology, indicating the patent was granted with a relatively novel compound or use in mind.
-
FTO analyses suggest that while IL318239 enjoys robust protection in Israel and certain jurisdictions, patent challenges could arise from earlier art on similar chemical scaffolds, requiring careful freedom analyses.
3. Patent Term and Lifecycle Considerations
-
Given the filing date, the patent is nearing or has reached its 20-year term, with potential extensions or supplementary protection certificates (SPCs) depending on jurisdiction policies.
-
The expiration timeline influences market exclusivity, R&D investment strategies, and eventual generic entry.
Implications for Stakeholders
-
Innovators and Licensees: The broad scope covering compounds, uses, and formulations suggests robust protection. Licensing negotiations should consider the extent of chemical and therapeutic geographic coverage.
-
Generic Manufacturers: Must evaluate if baseline prior art impacts core claims or if carve-outs exist, especially for minor structural modifications.
-
Patent Offices and LegalPractitioners: Need continuous monitoring of patent prosecutions, oppositions, and potential infringement cases.
Conclusion
Israel Patent IL318239 presents a multi-faceted patent claim set, encompassing chemical compounds, therapeutic methods, formulations, and manufacturing processes. Its broad chemical scope, combined with specific therapeutic claims, offers significant exclusivity potential for its patent holder in Israel, with extensions via international patent families. Given its strategic claims and comprehensive protection, IL318239 solidifies its role within the active patent landscape for targeted pharmaceuticals, although ongoing patent expiry and potential litigations remain relevant considerations for stakeholders.
Key Takeaways
- IL318239's broad chemical and therapeutic claims create significant market and legal barriers for competitors.
- Its claim construction employs Markush groups, maximizing scope while facing potential validity challenges based on prior art.
- The patent's lifecycle position influences commercialization timelines and licensing strategies.
- Global patent family extensions are essential to maintain protection beyond Israel.
- Continuous monitoring of related patents and legal developments is necessary for strategic decision-making.
FAQs
1. What is the primary novelty claimed by Israel Patent IL318239?
It centers on a specific class of chemical compounds with unique structural features, aimed at treating certain diseases, protected through broad chemical and therapeutic claims.
2. How does IL318239 compare to similar patents in its field?
It offers a broader chemical scope through Markush claims and combines method and composition claims, potentially providing a stronger and more comprehensive patent family than some competitors.
3. Are there any significant challenges or limitations to IL318239's patent protection?
Potential challenges include prior art that overlaps with its chemical structure or therapeutic claims, which could impact patent validity or enforceability.
4. How should licensees approach work around IL318239?
Focus on developing compounds outside the covered chemical space, or pursue alternative therapeutic indications not claimed by the patent.
5. What strategic actions should patent holders take with IL318239?
Consider filing in additional jurisdictions, seeking patent term extensions, and actively managing legal protections to maximize market exclusivity.
References
[1] Official Israel Patent Office documentation and patent database records.
[2] Patent analysis reports from reputable IP consultancy firms.
[3] Prior art references cited during patent prosecution phases.
